Buy
|
Original-Research: Nynomic AG - from NuWays AG
Classification of NuWays AG to Nynomic AG
Q4 prelims in line, returning to growth in FY25; chg. est. Topic: Nynomic released preliminary Q4 figures largely in line with expectations and a FY25 guidance, which reflects a return to growth. Yet, the expected FY25 growth guidance fell short of market expectations due to ongoing macroeconomic headwinds. Preliminary Q4 sales stood at € 30.5m, down roughly 12% yoy, as the trends witnessed during the first three quarters of the years have not reversed (as expected). For instance, Nynomic had to deal with a broad reluctance in regards to placements of new orders as customers remained cautious about shortterm economic developments. Within Clean Tech, customers in traditional silicon-based sectors are experiencing delays in new projects, as well as upgrades to existing systems, due to changes in the AI and memory markets, leading to postponements/delayed product call-offs. FY24p sales came in at € 102.5m, a 13% yoy decline. The order book at the end of Q4 stood at € 48m (-12% yoy). As a result the negative operating leverage, the preliminary Q4 EBIT decreased 66% yoy to € 2.4m with a margin of 7.8% (-12.9pp yoy). FY24p EBIT was down 51% at € 7.5m. Management released a conservative FY25 guidance, expecting € 105-110m sales and € 8.5-10m EBIT, which came in below market expectations of € 123m sales and € 15.8m EBIT. This is the result of a rather conservative approach by management following last year's guidance cut and continued significant uncertainties across the group's end markets. Despite continued short-term headwinds, management remains confident to be able to reach the mid-term guidance of at least € 200m sales and a 16-19% EBIT margin. Next to a return to strong organic growth (~ 10% p.a.), meeting the mid-term targets will be subject to acquisitions (€ 45m sales when assuming 10% organic CAGR from 2026e onwards). Organic growth should be stemming from a broad recovery of core end markets such as semiconductors, medical devices and pharmaceuticals, the group's R&D efforts bearing fruit (management mentioned a well-filled product development pipeline) and recent promising product launches. For instance, LayTec announced a strategic partnership, supplying advanced optical inspection tools for quality assurance in a state-of-the art thin film PV production line (perowskite solar glass). Last year, m-u-t launched the LabScanner Plus, a bulk-testing tool for pharmaceutical companies and in 2023 real-time analysis within a tablet press in cooperation with FETTE. Acquisitions: During the earnings call, management highlighted to be far along several M&A processes and mentioned confidence in the ability to close add-ons this year. Thanks to its strong balance sheet, the company should be able to handle a larger acquisition (eNuW: more than € 10m sales) with a focus on technological and/or geographical diversification. Conclusion: With macroeconomic headwinds likely to persist throughout FY25, Nynomic looks set to grow slower than management’s long-term annual organic growth expectation of roughly 10%. Yet, with ongoing R&D efforts and a strong project pipeline, the company should be well-positioned to reap the benefits once end markets recover. We confirm our BUY rating with a new € 34.5 PT (old: € 44) based on DCF. You can download the research here: http://www.more-ir.de/d/31962.pdf For additional information visit our website: https://www.nuways-ag.com/research-feed Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse. ++++++++++
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
||||||||||||||||||||
2099836 13.03.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.